MedTrace Logo

COMBOPROFEN for Treatment of Muscular Pain Associated With Delayed Onset Muscle Soreness (DOMS)

NCT03223519 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2018-01-23

No results posted yet for this study

Summary

The study is designed as a proof of concept, single-center, randomized, double-blind, placebo controlled study to assess the safety and efficacy of Comboprofen (Ibuprofen + Magnesium + Vitamin C) compared to placebo, Ibuprofen, Magnesium and Vitamin C monotherapies in the treatment of Delayed Onset Muscle Soreness (DOMS).

Conditions

  • Delayed Onset Muscle Soreness, DOMS

Interventions

DRUG

Comboprofen

Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days

DRUG

Placebo

Powder for oral solution administered TID for 3 days

DRUG

Ibuprofen

Powder for oral solution administered TID for 3 days

DRUG

Magnesium

Powder for oral solution administered TID for 3 days

DRUG

Vitamin C

Powder for oral solution administered TID for 3 days

Sponsors & Collaborators

  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    collaborator OTHER

  • Spherium Biomed

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-12
Primary Completion
2017-11-24
Completion
2017-11-28

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03223519 on ClinicalTrials.gov